A detailed history of Fuller & Thaler Asset Management, Inc. transactions in Guardant Health, Inc. stock. As of the latest transaction made, Fuller & Thaler Asset Management, Inc. holds 2,174,717 shares of GH stock, worth $65.7 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
2,174,717
Previous 1,938,515 12.18%
Holding current value
$65.7 Million
Previous $56 Million 10.93%
% of portfolio
0.2%
Previous 0.24%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$22.3 - $36.29 $5.27 Million - $8.57 Million
236,202 Added 12.18%
2,174,717 $49.9 Million
Q2 2024

Aug 09, 2024

BUY
$16.07 - $31.84 $31.2 Million - $61.7 Million
1,938,515 New
1,938,515 $56 Million
Q3 2021

Nov 10, 2021

SELL
$98.77 - $132.17 $9.16 Million - $12.3 Million
-92,709 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$109.77 - $165.68 $817,457 - $1.23 Million
-7,447 Reduced 7.44%
92,709 $11.5 Million
Q1 2021

May 13, 2021

BUY
$127.04 - $179.1 $116,622 - $164,413
918 Added 0.93%
100,156 $15.3 Million
Q4 2020

Feb 11, 2021

BUY
$99.96 - $135.93 $167,033 - $227,139
1,671 Added 1.71%
99,238 $12.8 Million
Q3 2020

Nov 09, 2020

BUY
$80.32 - $111.8 $87,629 - $121,973
1,091 Added 1.13%
97,567 $10.9 Million
Q2 2020

Aug 13, 2020

BUY
$60.49 - $97.5 $56,618 - $91,260
936 Added 0.98%
96,476 $7.83 Million
Q1 2020

May 06, 2020

SELL
$59.04 - $88.81 $85,667 - $128,863
-1,451 Reduced 1.5%
95,540 $6.65 Million
Q4 2019

Feb 14, 2020

SELL
$59.49 - $82.78 $92,685 - $128,971
-1,558 Reduced 1.58%
96,991 $7.58 Million
Q3 2019

Nov 13, 2019

SELL
$62.59 - $110.3 $56,706 - $99,931
-906 Reduced 0.91%
98,549 $6.29 Million
Q2 2019

Aug 13, 2019

BUY
$63.94 - $91.11 $6.36 Million - $9.06 Million
99,455 New
99,455 $8.59 Million

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.09B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Fuller & Thaler Asset Management, Inc. Portfolio

Follow Fuller & Thaler Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.